Drugs / ImmTOR
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03905512 | May 2019 → Aug 2020 | gout | Selecta Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ImmTOR | “SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.” PMID 37449908 ↗ Apr 2024 |
| Known as | SEL-110 | “SEL-212 [a combination of pegadricase (SEL-037) and ImmTOR (SEL-110)] or KRYSTEXXA® for 6 months.” NCT03905512 ↗ |
| Modality | Other / unclassified | “a proprietary rapamycin-containing nanoparticle (ImmTOR)” PMID 37449908 ↗ Apr 2024 |